NO.1 PHARMACY(SH:600833)2023-04-28 16:00Financial Performance - The company's operating revenue for Q1 2023 was CNY 459,099,405.27, representing a year-on-year increase of 17.29%[5] - Net profit attributable to shareholders reached CNY 29,612,934.80, a significant increase of 373.18% compared to the same period last year[5] - The net cash flow from operating activities was CNY 110,910,482.82, reflecting a year-on-year growth of 327.92%[5] - Basic earnings per share (EPS) stood at CNY 0.1327, up by 372.39% year-on-year[5] - The operating profit for Q1 2023 was CNY 13,131,911.76, compared to CNY 8,150,857.93 in Q1 2022, representing a year-over-year increase of 61.5%[17] - The total profit for Q1 2023 reached CNY 38,846,843.85, significantly higher than CNY 8,208,293.96 in Q1 2022, marking a substantial increase[17] - The net profit for Q1 2023 was CNY 29,612,934.80, a significant increase from CNY 6,258,328.50 in Q1 2022, representing a growth of approximately 373%[18] - Total comprehensive income for Q1 2023 was CNY 43,844,285.02, compared to CNY 54,842,713.95 in Q1 2022, indicating a decrease of about 20%[18] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,098,107,327.86, an increase of 2.89% from the end of the previous year[6] - The total assets as of March 31, 2023, amounted to CNY 2,098,107,327.86, compared to CNY 2,039,102,174.03 at the end of 2022, indicating a growth of 2.9%[14] - The total liabilities increased to CNY 1,095,584,963.71 as of March 31, 2023, from CNY 1,080,424,094.90 at the end of 2022, reflecting a rise of 1.4%[14] - The total equity attributable to shareholders rose to CNY 995,515,048.26 as of March 31, 2023, compared to CNY 951,670,763.24 at the end of 2022, an increase of 4.6%[14] Cash Flow - Cash and cash equivalents decreased to CNY 388,289,848.26 as of March 31, 2023, from CNY 504,932,742.28 at the end of 2022, a decline of 23.1%[12] - Operating cash flow for Q1 2023 was CNY 110,910,482.82, a turnaround from a negative cash flow of CNY -48,661,494.93 in Q1 2022[19] - Cash and cash equivalents at the end of Q1 2023 stood at CNY 387,989,848.26, up from CNY 151,071,135.14 in Q1 2022, reflecting an increase of approximately 156%[20] - The company reported a net cash outflow from investing activities of CNY -212,289,848.73 in Q1 2023, compared to CNY -42,102,569.55 in Q1 2022, indicating increased investment activity[20] - The total cash outflow from financing activities in Q1 2023 was CNY 15,052,939.22, compared to CNY 8,487,445.70 in Q1 2022, indicating an increase in financing costs[20] Shareholder Information - The company had a total of 31,656 common shareholders at the end of the reporting period[9] - The largest shareholder, Bailian Group Co., Ltd., held 44.95% of the shares, totaling 100,274,734 shares[9] Other Income and Expenses - The company reported a net other income of CNY 25,817,244.55 in Q1 2023, compared to CNY 105,731.44 in Q1 2022, showing a significant increase[17] - The company incurred tax expenses of CNY 9,233,909.05 in Q1 2023, compared to CNY 1,949,965.46 in Q1 2022, reflecting an increase of about 373%[18] - Other comprehensive income after tax for Q1 2023 was CNY 14,231,350.22, down from CNY 48,584,385.45 in Q1 2022, showing a decrease of approximately 71%[18] Inventory and Costs - The total operating costs for Q1 2023 were CNY 449,236,452.47, up from CNY 383,410,691.60 in Q1 2022, reflecting a growth of 17.2%[17] - Inventory decreased to CNY 326,159,275.61 as of March 31, 2023, from CNY 334,753,732.46 at the end of 2022, a decline of 2.6%[12]